ICON plc

ICON plc is a Dublin, Ireland-headquartered global clinical research organization (CRO) founded in 1990 that provides outsourced drug development services to pharmaceutical, biotechnology, medical device, and government research organizations. Following its 2021 merger with PRA Health Sciences, ICON became the second-largest CRO globally, offering integrated services spanning clinical trial design and execution, regulatory strategy, pharmacovigilance, laboratory services, data management, and commercialization support. For academic investigators and biotech companies conducting clinical research, ICON provides the regulatory expertise, site management capabilities, and biostatistics support needed to design and execute scientifically rigorous trials that meet regulatory standards for marketing authorization. Their Accellacare site network comprises dedicated research sites with pre-screened patient populations and trained clinical research professionals enabling rapid trial startup. ICON's FIRECREST clinical trial management platform provides electronic data capture, patient-facing digital tools, and clinical trial transparency infrastructure. Their early development services, including phase I units and translational medicine capabilities, bridge the gap between preclinical data and first-in-human studies for academic investigators. ICON's Scientific Operations team includes therapeutic area specialists in oncology, neuroscience, infectious disease, and cardiovascular medicine who support investigators in protocol design and endpoint selection. Their imaging CRO capabilities for centralized reading of CT, MRI, and PET images are critical to clinical oncology trials using imaging biomarkers as endpoints, and their large outcomes data resources support real-world evidence generation.